Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -410.19 KRW | -187.66% |
| 2022 | 467.91 KRW | -56.41% |
| 2021 | 1073.38 KRW | -57.22% |
| 2020 | 2508.88 KRW | 795.25% |
| 2019 | -360.86 KRW | 15.6% |
| 2018 | -427.57 KRW | 20.73% |
| 2017 | -539.41 KRW | 37.53% |
| 2016 | -863.44 KRW | -148.41% |
| 2015 | -347.58 KRW | 64.96% |
| 2014 | -992.00 KRW | -75.58% |
| 2013 | -565.00 KRW | 11.72% |
| 2012 | -640.00 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -71.95 KRW | -348.96% |
| 2024 Q3 | -401.97 KRW | -511.65% |
| 2024 Q1 | 28.90 KRW | 105.82% |
| 2023 Q4 | -496.65 KRW | -2793.33% |
| 2023 Q1 | -18.11 KRW | 92.12% |
| 2023 Q3 | 18.44 KRW | -78.59% |
| 2023 FY | - KRW | -187.66% |
| 2023 Q2 | 86.13 KRW | 575.59% |
| 2022 Q3 | 335.13 KRW | 1202.99% |
| 2022 Q2 | 25.72 KRW | -92.36% |
| 2022 FY | - KRW | -56.41% |
| 2022 Q1 | 336.79 KRW | 67.57% |
| 2022 Q4 | -229.74 KRW | -168.55% |
| 2021 Q3 | -386.23 KRW | -158.7% |
| 2021 Q2 | 657.99 KRW | 9.05% |
| 2021 Q4 | 200.98 KRW | 152.04% |
| 2021 FY | - KRW | -57.22% |
| 2021 Q1 | 603.39 KRW | -49.47% |
| 2020 Q2 | 1815.57 KRW | 295.43% |
| 2020 Q3 | 116.00 KRW | -93.61% |
| 2020 Q4 | 1194.07 KRW | 929.37% |
| 2020 Q1 | -928.99 KRW | -595.25% |
| 2020 FY | - KRW | 795.25% |
| 2019 Q1 | -131.50 KRW | -22.9% |
| 2019 FY | - KRW | 15.6% |
| 2019 Q4 | -133.62 KRW | -108.78% |
| 2019 Q2 | -33.61 KRW | 74.44% |
| 2019 Q3 | -64.00 KRW | -90.42% |
| 2018 Q4 | -107.00 KRW | 13.04% |
| 2018 Q2 | -34.06 KRW | 79.3% |
| 2018 Q1 | -164.55 KRW | 26.92% |
| 2018 FY | - KRW | 20.73% |
| 2018 Q3 | -123.05 KRW | -261.27% |
| 2017 Q1 | -157.65 KRW | 3.45% |
| 2017 FY | - KRW | 37.53% |
| 2017 Q4 | -225.15 KRW | -217.11% |
| 2017 Q2 | -79.03 KRW | 49.87% |
| 2017 Q3 | -71.00 KRW | 10.16% |
| 2016 FY | - KRW | -148.41% |
| 2016 Q1 | -185.93 KRW | -110.19% |
| 2016 Q2 | -258.46 KRW | -39.01% |
| 2016 Q4 | -163.29 KRW | 57.59% |
| 2016 Q3 | -385.00 KRW | -48.96% |
| 2015 Q4 | -88.46 KRW | -580.46% |
| 2015 Q2 | -83.78 KRW | 55.72% |
| 2015 Q1 | -189.19 KRW | -6.41% |
| 2015 FY | - KRW | 64.96% |
| 2015 Q3 | -13.00 KRW | 84.48% |
| 2014 Q3 | -315.00 KRW | 5.67% |
| 2014 Q1 | -162.35 KRW | 33.21% |
| 2014 FY | - KRW | -75.58% |
| 2014 Q4 | -177.79 KRW | 43.56% |
| 2014 Q2 | -333.93 KRW | -105.69% |
| 2013 Q2 | -39.00 KRW | -104.83% |
| 2013 Q4 | -243.07 KRW | 6.51% |
| 2013 Q3 | -260.00 KRW | -566.67% |
| 2013 Q1 | -19.04 KRW | 76.96% |
| 2013 FY | - KRW | 11.72% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | -82.65 KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| HLB Co., Ltd. | -1559.61 KRW | 73.699% |
| iNtRON Biotechnology, Inc. | -292.11 KRW | -40.423% |
| BINEX Co., Ltd. | 151.04 KRW | 371.577% |
| Anterogen.Co.,Ltd. | -291.93 KRW | -40.51% |
| MEDIPOST Co., Ltd. | 287.00 KRW | 242.923% |
| CrystalGenomics, Inc. | -661.00 KRW | 37.944% |
| Helixmith Co., Ltd | -1543.76 KRW | 73.429% |
| Chabiotech Co.,Ltd. | -149.80 KRW | -173.825% |
| Medy-Tox Inc. | 1456.65 KRW | 128.16% |
| Peptron, Inc. | -773.61 KRW | 46.977% |
| Amicogen, Inc. | -583.58 KRW | 29.711% |
| Genexine, Inc. | -1652.14 KRW | 75.172% |
| HLB Therapeutics Co.,Ltd. | -32.12 KRW | -1177.055% |
| LegoChem Biosciences, Inc. | -2595.00 KRW | 84.193% |
| ALTEOGEN Inc. | -65.27 KRW | -528.451% |
| PharmaResearch Co., Ltd. | 7502.00 KRW | 105.468% |
| SillaJen, Inc. | -179.98 KRW | -127.909% |
| JETEMA, Co., Ltd. | 783.21 KRW | 152.373% |
| OliX Pharmaceuticals,Inc | -1323.81 KRW | 69.014% |
| Genomictree Inc. | -391.00 KRW | -4.908% |
| MedPacto, Inc. | -1664.87 KRW | 75.362% |
| D&D Pharmatech | 409.19 KRW | 200.244% |
| EASY BIO,Inc. | 455.00 KRW | 190.152% |
| GI Innovation, Inc. | -1285.69 KRW | 68.096% |